Veradermics to present phase 3 hair loss trial results Monday

Veradermics, Incorporated will hold an investor call on Monday at 8:00 am ET to unveil the key findings from Part B of its Phase 3 clinical trial assessing VDPHL01 for treating pattern hair loss, according to a press release. The double-blind, placebo-controlled registration-directed trial, known as Study 302, recruited more than 500 males experiencing mild-to-moderate pattern hair loss.

The study examined VDPHL01, an extended-release oral minoxidil formulation. The presentation and related slides will be accessible on the Events page of Veradermics' Investors section on its website. A replay will be available post-call. VDPHL01 is an investigational oral non-hormonal drug currently in Phase 3 development for addressing pattern hair loss in both men and women.

The extended-release formulation features a gel matrix to ensure steady absorption of minoxidil. Pattern hair loss, also referred to as androgenetic alopecia, affects approximately 80 million individuals in the United States, encompassing 30 million women and 50 million men. For the past nearly 30 years, no FDA-approved prescription medications have been introduced for pattern hair loss.

Veradermics describes itself as a dermatologist-founded, late clinical-stage biopharmaceutical company dedicated to developing therapies for pattern hair loss.